GLUCAGON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
GLUCAGON by Eli Lilly and Company is 12. Approved for severe hypoglycemia in pediatric. First approved in 1960.
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is a small-molecule injection used to treat severe hypoglycemia in pediatric patients by activating hepatic glucagon receptors to stimulate glycogen breakdown and glucose release from the liver. Blood glucose concentrations rise within 10 minutes of subcutaneous injection, with peak levels (~136-138 mg/dL) achieved within 26-30 minutes. The drug also functions as a diagnostic aid during radiological examinations.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial teams should anticipate market contraction and focus on generic transition planning.
Mechanism of Action
12.1 Mechanism of Action Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic…
Worked on GLUCAGON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.